<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676091</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-012</org_study_id>
    <nct_id>NCT00676091</nct_id>
  </id_info>
  <brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to analyze 13-valent pneumococcal vaccine given to healthy
      infants in Brazil for safety and tolerability, and to determine the immune response to the
      vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</measure>
    <time_frame>1 Month after the infant series (7 Months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥5 Enzyme-linked Immunosorbent Assay (ELISA) Units Per mL (EU/mL) for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series (7 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Mcg/mL in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥5 EU/mL for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥5 EU/mL along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) are presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">354</enrollment>
  <condition>Vaccines, Pneumococcal Conjugate Vaccine</condition>
  <arm_group>
    <arm_group_label>13vPnC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7vPnC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-Valent Pneumococcal Conjugate Vaccine (13vPnC)</intervention_name>
    <arm_group_label>13vPnC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-Valent Pneumococcal Conjugate Vaccine (7vPnc)</intervention_name>
    <arm_group_label>7vPnC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy 1 month old infants

          -  Available for the duration of the study and reachable by telephone

          -  Able to complete two blood drawing procedures during the study

        Exclusion criteria:

          -  Previous vaccination, contraindication or history of allergic reaction to vaccine or
             vaccine components

          -  Bleeding disorder, immune deficiency or significant chronic or congenital disease

          -  Previous receipt of blood products or immune globulin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>54 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florianopolis</city>
        <zip>88025-301</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sau Paulo</city>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sau Paulo</city>
        <zip>04038-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <results_first_submitted>September 22, 2010</results_first_submitted>
  <results_first_submitted_qc>September 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2010</results_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <keyword>Pneumococcal conjugate vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="P2">
          <title>7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Parent or legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Died prior to receiving 7vPnC</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent or legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B2">
          <title>7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="163"/>
            <count group_id="B2" value="162"/>
            <count group_id="B3" value="325"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="0.2"/>
                    <measurement group_id="B2" value="2.2" spread="0.2"/>
                    <measurement group_id="B3" value="2.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>1 Month after the infant series (7 Months of age)</time_frame>
        <population>Evaluable immunogenicity population: treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population: treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="92.7" upper_limit="99.0"/>
                    <measurement group_id="O2" value="95.6" lower_limit="91.1" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="94.5" upper_limit="99.6"/>
                    <measurement group_id="O2" value="97.5" lower_limit="93.6" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="93.6" upper_limit="99.3"/>
                    <measurement group_id="O2" value="98.1" lower_limit="94.5" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" lower_limit="89.3" upper_limit="97.3"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="92.7" upper_limit="99.0"/>
                    <measurement group_id="O2" value="93.0" lower_limit="87.8" upper_limit="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.7" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" lower_limit="80.8" upper_limit="91.9"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.8" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="38.2" lower_limit="30.4" upper_limit="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="93.6" upper_limit="99.3"/>
                    <measurement group_id="O2" value="52.6" lower_limit="44.4" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.2" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.4" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥5 Enzyme-linked Immunosorbent Assay (ELISA) Units Per mL (EU/mL) for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) are presented.</description>
        <time_frame>1 month after the infant series (7 months of age)</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the given concomitant vaccine component.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥5 Enzyme-linked Immunosorbent Assay (ELISA) Units Per mL (EU/mL) for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) are presented.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the given concomitant vaccine component.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT ≥5 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" lower_limit="28.4" upper_limit="44.0"/>
                    <measurement group_id="O2" value="32.3" lower_limit="25.1" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA ≥5 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" lower_limit="62.2" upper_limit="77.2"/>
                    <measurement group_id="O2" value="71.5" lower_limit="63.8" upper_limit="78.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRN ≥5 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" lower_limit="88.5" upper_limit="96.9"/>
                    <measurement group_id="O2" value="96.2" lower_limit="91.9" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Mcg/mL in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Mcg/mL in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="93.4" upper_limit="99.3"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.3" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="96.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="96.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.3" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.3" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.7" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="86.5" upper_limit="95.8"/>
                    <measurement group_id="O2" value="7.5" lower_limit="3.8" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="72.1" lower_limit="63.9" upper_limit="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="92.1" lower_limit="86.5" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.5" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥5 EU/mL for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥5 EU/mL along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) are presented.</description>
        <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the given concomitant vaccine component.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥5 EU/mL for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥5 EU/mL along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], and pertactin [PRN]) are presented.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the given concomitant vaccine component.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT ≥5 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" lower_limit="42.4" upper_limit="58.9"/>
                    <measurement group_id="O2" value="49.3" lower_limit="41.1" upper_limit="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA ≥5 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="85.8" upper_limit="95.4"/>
                    <measurement group_id="O2" value="88.8" lower_limit="82.7" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRN ≥5 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="96.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.3" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)</title>
        <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 1 (2 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)</title>
          <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)</title>
        <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 2 (4 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)</title>
          <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)</title>
        <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 3 (6 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)</title>
          <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                    <measurement group_id="O2" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)</title>
        <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after toddler dose (12 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)</title>
          <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3"/>
                    <measurement group_id="O2" value="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 1 (2 Months of Age)</title>
        <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 1 (2 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 1 (2 Months of Age)</title>
          <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3"/>
                    <measurement group_id="O2" value="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6"/>
                    <measurement group_id="O2" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)</title>
        <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 2 (4 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)</title>
          <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4"/>
                    <measurement group_id="O2" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 3 (6 Months of Age)</title>
        <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 3 (6 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 3 (6 Months of Age)</title>
          <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6"/>
                    <measurement group_id="O2" value="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events: Toddler Dose (12 Months of Age)</title>
        <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after toddler dose (12 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events: Toddler Dose (12 Months of Age)</title>
          <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2"/>
                    <measurement group_id="O2" value="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through 1 Month after last study vaccination (13 Months). Local reactions and systemic events assessed within 4 days of dose: Infant Series Dose 1=2 months of age; Dose 2=4 months of age; Dose 3=6 months of age; Toddler Dose=12 months of age.</time_frame>
      <desc>Safety population = all randomized subjects with at least 1 dose of study treatment. An Adverse Event (AE) term may be reported as both a serious and non-serious AE, but are distinct events. AE may = serious for 1 subject and = non-serious for another subject or subject may have experienced both a serious and non-serious episode of the same event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Infant Series 13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series).</description>
        </group>
        <group group_id="E2">
          <title>Infant Series 7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series).</description>
        </group>
        <group group_id="E3">
          <title>After the Infant Series 13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series); assessment 1 month after the infant series (7 months of age).</description>
        </group>
        <group group_id="E4">
          <title>After the Infant Series 7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series); assessment 1 month after the infant series (7 months of age).</description>
        </group>
        <group group_id="E5">
          <title>Toddler Dose 13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 mL dose administered IM at 12 months of age (toddler dose).
7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 12 months of age (toddler dose).
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (non-solicited) Other Adverse Events N=69; systematic (solicited) Local Reactions N=81; systematic (solicited) Systemic Events N=84. Total N at Risk=155: 1 participant had no record of safety information during the Toddler dose period and was not included in the Safety population.</description>
        </group>
        <group group_id="E6">
          <title>Toddler Dose 7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 12 months of age (toddler dose).
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (non-solicited) Other Adverse Events N=64; systematic (solicited) Local Reactions N=67; systematic (solicited) Systemic Events N=86.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotonic-hyporesponsive episode</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="84" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="86" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Congenital hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Glucose-6-phosphate dehydrogenase deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Oral mucosal discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Injection site exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Injection site scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Vaccination site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥ 38 degrees Celsius [C] but ≤ 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever ≥ 38 degrees C but ≤ 39 degrees C</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="116"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥ 38 degrees C but ≤ 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever ≥ 38 degrees C but ≤ 39 degrees C</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥ 38 degrees C but ≤ 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever ≥ 38 degrees C but ≤ 39 degrees C</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 39 degrees C but ≤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt; 39 degrees C but ≤ 40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 39 degrees C but ≤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt; 39 degrees C but ≤ 40 degrees C</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 39 degrees C but ≤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt; 39 degrees C but ≤ 40 degrees C</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt; 40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt; 40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt; 40 degrees C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="143"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="117"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability</description>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="84" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="86" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Irritability</description>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep</description>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="117"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Increased sleep</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="119"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to anthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Allergy to anthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Perineal infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Menigitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Abnormal weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotonic-hyporesponsive episode</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Psychomotor skills impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pityriasis alba</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; tenderness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="81" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="67" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; tenderness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; tenderness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (significant)=present and interfered with limb movement</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (significant)=present and interfered with limb movement</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (significant)=present and interfered with limb movement</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Swelling (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Swelling (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Swelling (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Swelling (mild)=0.5 to 2.0 centimeters (cm)</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Swelling (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Swelling (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Swelling (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Swelling (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Swelling (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Swelling (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Swelling (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Swelling (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Redness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Redness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Redness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Redness (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Redness (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Redness (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Redness (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Redness (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Redness (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Redness (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Redness (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Redness (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

